in January of 2018, Glen Research Corporation was aquired by Maravai Life Sciences, a biopharmaceutical company that is part of the portfolio of Chicago-based private equity firm GTCR. Glen Research specializes in the production of a wide range of reagents used in the synthesis of DNA and RNA. The firm produces CE phosphoramidites and other products which are starting chemicals for DNA synthesis and manufactures synthetic DNA purification systems. Maravai's acquisition of Glen Research was seen as part of that Maravai's increasing investment in genomics research oppurtunities,
